Cannabinoids and psychedelics are poised to become breakthrough therapies for a range of debilitating conditions. However, issues with the cost-effective and scalable production of these API's, as well as pharmacokinetic issues such as low solubility, bioavailability and stability limit their application. Octarine produces these complex molecules at scale with yeast fermentation, and further, uses proprietary enzymatic modification technology to produce novel derivatives with improved properties
